October 3, 2018
Takeda Pharmaceutical and Seattle Genetics said on October 2 that the lymphoma treatment Adcetris (brentuximab vedotin) demonstrated a statistically significant improvement in progression-free survival (PFS) in a multinational PIII clinical study, against the control arm. The PIII trial, dubbed ECHELON-2,...read more